- Issuer ticker
-
APLS
- Reported as of
-
09 Jun 2025
- Net transaction value
-
+$1,599,675
- SEC form
-
4
- Accepted by SEC
-
11 Jun 2025, 16:19:13 UTC
Filing notes and source
Key filing fact
Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 11 Jun 2025.
Key facts
- This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 11 Jun 2025, 16:19.
Change
- Previous filing in this sequence was filed on 22 May 2025.
- Current net transaction value: +$1,599,675.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
Ownership activity is grounded in SEC Form 4 disclosures.
View source filing
Reporting Owners (1)
CIK 0001657720
Primary reporting owner
Deschatelets Pascal
- Relationship
-
Chief Scientific Officer
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $1,599,675
- Shares
- +82,500
- Change %
- Price
-
$19.39
- Shares after
- 82,500
- Date
- 09 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 82,500
- Exercise price
- $19.39
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Explanation of responses
1 footnote